Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia

dc.contributor.authorRodríguez, Fausto J.
dc.contributor.authorBrosnan-Cashman, Jacqueline A.
dc.contributor.authorAllen, Sariah J.
dc.contributor.authorVizcaíno, Maria Adelita
dc.contributor.authorGiannini, Caterina
dc.contributor.authorCamelo-Piragua, Sandra Ines
dc.contributor.authorWebb, Milad
dc.contributor.authorMatsushita, Marcus De Medeiros
dc.contributor.authorWadhwani, Nitin R.
dc.contributor.authorTabbarah, Abeer Z.
dc.contributor.authorHamideh, Dima
dc.contributor.authorJiang, Liqun
dc.contributor.authorChen, Liam L.
dc.contributor.authorArvanitis, Leonidas D.
dc.contributor.authorAlnajar, Hussein H.
dc.contributor.authorBarber, John R.
dc.contributor.authorRodríguez-Velasco, Alicia
dc.contributor.authorOrr, Brent A.
dc.contributor.authorHeaphy, Christopher M.
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:03Z
dc.date.available2025-01-24T12:10:03Z
dc.date.issued2019
dc.description.abstractAnaplasia may be identified in a subset of tumors with a presumed pilocytic astrocytoma (PA) component or piloid features, which may be associated with aggressive behavior, but the biologic basis of this change remains unclear. Fifty-seven resections from 36 patients (23 M, 13 F, mean age 32 years, range 3–75) were included. A clinical diagnosis of NF1 was present in 8 (22%). Alternative lengthening of telomeres (ALT) was assessed by telomere-specific FISH and/or CISH. A combination of immunohistochemistry, DNA sequencing and FISH were used to study BRAF, ATRX, CDKN2A/p16, mutant IDH1 p.R132H and H3-K27M proteins. ALT was present in 25 (69%) cases and ATRX loss in 20 (57%), mostly in the expected association of ALT+/ATRX- (20/24, 83%) or ALT-/ATRX+ (11/11, 100%). BRAF duplication was present in 8 (of 26) (31%). H3-K27M was present in 5 of 32 (16%) cases, all with concurrent ATRX loss and ALT. ALT was also present in 9 (of 11) cases in the benign PA precursor, 7 of which also had ATRX loss in both the precursor and the anaplastic tumor. In a single pediatric case, ALT and ATRX loss developed in the anaplastic component only, and in another adult case, ALT was present in the PA-A component only, but ATRX was not tested. Features associated with worse prognosis included subtotal resection, adult vs. pediatric, presence of a PA precursor preceding a diagnosis of anaplasia, necrosis, presence of ALT and ATRX expression loss. ALT and ATRX loss, as well as alterations involving the MAPK pathway, are frequent in PA with anaplasia at the time of development of anaplasia or in their precursors. Additionally, a small subset of PA with anaplasia have H3-K27M mutations. These findings further support the concept that PA with anaplasia is a neoplasm with heterogeneous genetic features and alterations typical of both PA and diffuse gliomas. © 2018 International Society of Neuropathology
dc.identifier.doihttps://doi.org/10.1111/bpa.12646
dc.identifier.eid2-s2.0-85055198744
dc.identifier.pmid30192422
dc.identifier.urihttp://hdl.handle.net/10938/32236
dc.language.isoen
dc.publisherBlackwell Publishing Ltd
dc.relation.ispartofBrain Pathology
dc.sourceScopus
dc.subjectAlternative lengthening of telomeres
dc.subjectAtrx
dc.subjectGlioma
dc.subjectH3-k27m
dc.subjectPilocytic astrocytoma
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAnaplasia
dc.subjectAstrocytoma
dc.subjectBiomarkers, tumor
dc.subjectBrain
dc.subjectBrain neoplasms
dc.subjectChild
dc.subjectChild, preschool
dc.subjectFemale
dc.subjectHistones
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectIn situ hybridization, fluorescence
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMutation
dc.subjectNuclear proteins
dc.subjectTelomere
dc.subjectTelomere homeostasis
dc.subjectX-linked nuclear protein
dc.subjectAntineoplastic agent
dc.subjectB raf kinase
dc.subjectCyclin dependent kinase inhibitor 2a
dc.subjectH3 k27m protein
dc.subjectIsocitrate dehydrogenase 1
dc.subjectProtein
dc.subjectProtein p16
dc.subjectTranscriptional regulator atrx
dc.subjectUnclassified drug
dc.subjectAtrx protein, human
dc.subjectHistone
dc.subjectNuclear protein
dc.subjectTumor marker
dc.subjectAnaplastic carcinoma
dc.subjectAntibody labeling
dc.subjectArticle
dc.subjectBrain histology
dc.subjectBrain third ventricle
dc.subjectCancer chemotherapy
dc.subjectCancer prognosis
dc.subjectCancer radiotherapy
dc.subjectCancer recurrence
dc.subjectCancer survival
dc.subjectCerebellum
dc.subjectChromogenic in situ hybridization
dc.subjectClinical article
dc.subjectDna sequence
dc.subjectFluorescence in situ hybridization
dc.subjectGene loss
dc.subjectGene mutation
dc.subjectHistopathology
dc.subjectHuman
dc.subjectHuman tissue
dc.subjectImmunophenotyping
dc.subjectImmunoreactivity
dc.subjectIn situ hybridization
dc.subjectIrradiation
dc.subjectLongitudinal study
dc.subjectNeurofibromatosis type 1
dc.subjectNext generation sequencing
dc.subjectOverall survival
dc.subjectPosterior fossa
dc.subjectPreschool child
dc.subjectProgression free survival
dc.subjectSchool child
dc.subjectSpinal cord
dc.subjectYoung adult
dc.subjectBrain tumor
dc.subjectGenetics
dc.subjectMetabolism
dc.subjectPathology
dc.subjectPhysiology
dc.titleAlternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019-7849.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format